N4 Pharma PLC Operational Update (3436Z)
14 Septembre 2022 - 8:01AM
UK Regulatory
TIDMN4P
RNS Number : 3436Z
N4 Pharma PLC
14 September 2022
14 September 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Operational Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R) , a novel delivery system for cancer treatments
and vaccines, is pleased to provide an operational update on its
development plans for commercialising Nuvec(R) .
On 13 June 2022 and 15 July 2022, the Company provided updates
that in vivo investigations of Nuvec(R) loaded with various doses
of TNF alpha had showed clear tumour suppression and that the
Company had successfully loaded Nuvec(R) with siRNA and shown a
good in-vitro knockdown response.
T he Company has now completed initial testing on loading
Nuvec(R) with two generic siRNA probes, GFP (Green Fluorescent
protein) and EHMT-2 (Euchromatic Histone Lysine Methyltransferase 2
) at the same time. The Company's next step will be to test in
vitro whether Nuvec(R) loaded with both forms of siRNA is able to
silence both targets, which has already been demonstrated with
singular loading.
Following this work, the Company has undertaken a review of
where it believes it will likely get greatest traction to allow a
commercial license deal to be agreed, in addition to the ongoing
MTA work it already has in place.
After the development of successful mRNA vaccines, major
companies in this space appear to be focusing future development on
gene therapy treatments in particular using siRNA to silence
identified pathways involved in cancer. Given the pre-clinical
status of Nuvec(R) , the Company believes that focusing its work on
loading more than one siRNA sequence onto the same nanoparticle
will result in silencing of complimentary pathways leading to an
increased therapeutic response and establish a significant
differential in this marketplace.
Having established the capability of Nuvec(R) to carry two siRNA
species and provide a functional response, the Company is now
undertaking a series of experiments over the coming months using
two siRNA sequences directed against known, and clinically
validated, oncology targets. Specifically, the targets are the EGFR
signalling pathway, which regulates cell cycle progression and
BCl-2, which regulates apoptosis, a form of programmed cell death.
Silencing of the EGFR pathway is expected to inhibit cell division
while silencing BCl-2 will promote apoptosis and the potential for
additive or synergistic effects will be explored. Initial studies
will be conducted in vitro using a lung cancer cell line. This will
be followed by in vivo studies in mice.
Further updates will be provided as this programme of work
progresses.
Nigel Theobald, Chief Executive Officer of the Company,
commented :
"The world of vaccines and cancer therapy development is a fast
changing one and the wide applicability of Nuvec (R) as a delivery
system leaves us well placed to adapt to this ever-changing
climate.
"We have now identified a very strong commercial point of
difference for Nuvec(R) in that it can be successfully loaded with
at least two siRNA genes and maintain a monodisperse formulation.
The area of combination cancer treatments is attracting a lot of
interest and investment and siRNA is an exciting and growing area
for clinical development. Our research has shown over 300 companies
active in the RNA gene therapy space with 106 clinical trials using
siRNA already underway and likely many more to follow.
"Vaccine developers are looking to use their existing tried and
tested systems in late-stage clinical work but companies working
with siRNA are much more open to using novel delivery systems with
a strong point of difference and are mainly focused in early-stage
clinical work making this an ideal space for Nuvec (R) . Our
vaccine work is reliant on finding a partner to take Nuvec (R) into
clinical development, however using the siRNA genes EGFR and BCl-2
allows us to demonstrate the efficacy of using Nuvec (R) ourselves
in a proven clinical model, without major investment.
"We remain well funded to complete the next phases of our siRNA
work and present this data to Companies working in this space with
a view to licensing Nuvec (R) ."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 which has been
incorporated into UK law by the European Union (Withdrawal) Act
2018.
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470
Nominated Adviser and Joint Broker 0470
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
IFC Advisory Limited Tel: +44 (0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBKNBPABKDQCD
(END) Dow Jones Newswires
September 14, 2022 02:01 ET (06:01 GMT)
N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024